Genetically modified rat that expresses an F54L Txn1 mutant
US11970706B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Dec 6, 2018 |
| Grant date | Apr 30, 2024 |
| Priority date | — |
| Expiry date | Mar 23, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2015/8527
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Provided is a nonhuman animal model that is obtained by modifying a gene encoding thioredoxin and useful as a disease model of aging, kidney diseases, cardiovascular diseases, hypertension, aortic dissection, chronic obstructive lung disease, age-dependent epilepsy, abnormality of lipid metabolism, anemia, osteoporosis, abnormal immunity, etc. These variety of phenotypes are caused by the fact that a modification of a gene encoding thioredoxin induces hypofunction of thioredoxin expressed in multiple organs throughout the body. The gene encoding thioredoxin is a gene selected from among TXN, TRX, TRX1, RRDX, Txn1, Txn, Trx1 and ADF.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.